Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alto Neuroscience, Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness of its drug ALTO-100 for treating major depressive disorder (MDD) [4][6]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $50,000 in Alto to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Alto, with a deadline of September 19, 2025, for investors to seek the role of lead plaintiff [4]. - The complaint alleges that Alto and its executives made false statements regarding ALTO-100's effectiveness and overstated the company's business and financial prospects [6]. Group 2: Stock Performance and Market Reaction - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial, leading to a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [7]. - Following the announcement, analysts, including Jeffries, reduced their price target for Alto from $33 to $17, expressing concerns about the company's biomarker approach to CNS disorders and psychiatry [8].

Core Insights - Fiserv, Inc. has revised its 2025 outlook for refined organic revenue growth from a previous range of 10-12% to a flat 10% due to delays in company launches and initiatives [2] - Following the announcement of the revised guidance, Fiserv's stock price experienced a significant decline of over 17%, opening at $137.00 per share on July 23, 2025 [3] Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Fiserv on behalf of stockholders, focusing on possible violations of federal securities laws and other unlawful business practices [1] - The law firm encourages investors who have suffered losses to contact them for discussions regarding their legal rights [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Flywire To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Flywire between February 28, 2024 and February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 30, 2025 (GLO ...

Core Insights - The J.M. Smucker Company is under investigation for potential violations of federal securities laws and unlawful business practices [1][3] Financial Performance - On November 7, 2023, Smucker completed the acquisition of Hostess Brands for approximately $5.5 billion, with $2.4 billion recorded as goodwill in the Sweet Baked Snacks segment [3] - For Q3 2025, Smucker reported a comparable net sales decrease of 8% in the Sweet Baked Snacks segment, alongside a $794 million impairment charge related to goodwill and a $208 million impairment charge for the Hostess Brand trademark [3] - In Q4 2025, Smucker experienced a further 14% decrease in comparable net sales in the Sweet Baked Snacks segment, incurring an additional $867 million impairment charge for goodwill and a $113 million impairment charge for the Hostess Brand trademark [4] - Following the disappointing Q4 results, Smucker's share price fell by $17.44, or approximately 15.59%, closing at $94.41 per share on June 10, 2025 [4] Strategic Outlook - The company updated its 2026 financial plan to reflect decreased net sales in the Sweet Baked Snacks segment, indicating sustained underperformance since the acquisition of Hostess Brands [4]

Core Viewpoint - Wolf Haldenstein Adler Freeman & Herz LLP is investigating claims against P3 Health Partners, Inc. regarding potential violations of federal securities laws due to misleading statements made by the company and its executives [1][2]. Summary by Relevant Sections Allegations and Investigation Focus - The investigation aims to determine if P3 Health Partners and its officers made false or misleading statements that violated federal securities laws [1]. Triggering Events - On November 12, 2024, P3 reported disappointing financial results, including a negative adjusted EBITDA of $15 million due to a write-down of midyear risk adjustment receivables, and an additional $10 million in expenses from negative medical claims developments. The company also incurred another $10 million in network and operating expenses. As a result, the stock price plummeted from $19.50 to $10.45, marking a decline of 46.4% within two days [2][5]. - On March 28, 2025, P3 disclosed in its annual Form 10-K that it received a civil investigative demand from the Department of Justice regarding its marketing practices and remuneration for Medicare Advantage brokers and related parties [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against iRobot Corporation due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by September 5, 2025 [3][5]. Group 1: Allegations Against iRobot - The complaint alleges that iRobot and its executives made false and misleading statements regarding the effectiveness of their Restructuring Plan following the termination of the Amazon Acquisition [5]. - It is claimed that iRobot overstated its ability to operate profitably as a standalone company, raising substantial doubt about its ability to continue as a going concern [5]. - The company's public statements were deemed materially false and misleading at all relevant times [5]. Group 2: Financial Performance - iRobot reported a loss of $2.06 per share on revenue of $172 million for Q4 and full year 2024, marking a 44% year-over-year decline [6]. - The company expressed uncertainty regarding the success of new product launches due to various factors, including consumer demand and macroeconomic conditions, indicating substantial doubt about its financial viability for at least 12 months [6]. Group 3: Market Reaction - Following the release of the financial results, iRobot's stock price fell by $3.255 per share, or 51.58%, closing at $3.055 per share on March 13, 2025 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Capricor Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its lead drug candidate, deramiocel, and its regulatory status with the FDA [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Capricor between October 9, 2024, and July 10, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Capricor, with a deadline of September 15, 2025, for investors to seek the role of lead plaintiff [3][8]. - The complaint alleges that Capricor and its executives made false and misleading statements regarding the drug deramiocel and its FDA approval process [5]. Group 2: Regulatory Issues and Stock Performance - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying its Biologics License Application (BLA) due to insufficient evidence of effectiveness and the need for additional clinical data [6]. - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, indicating a significant market reaction to the news [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for allegedly making materially false and misleading statements regarding its business and operations during the pandemic period [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of California on behalf of investors who purchased Petco securities between January 14, 2021, and June 5, 2025 [1]. - Investors have until August 29, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Petco - The lawsuit alleges that Petco's pandemic-related business advantages were unsustainable and that its business model focused on premium pet food was flawed [3]. - It is claimed that the strength of Petco's differentiated product strategy was overstated, and the company downplayed the severity of the issues it faced [3]. - The defendants are accused of overstating Petco's ability to achieve sustainable and profitable growth [3].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In iRobot To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in iRobot between January 29, 2024 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 16, 2025 (GLOBE NEW ...

Core Viewpoint - A securities class action lawsuit has been filed against XPLR Infrastructure, LP, alleging misleading statements and omissions regarding the company's financial condition and business model during the class period from September 27, 2023, to January 27, 2025 [1][3]. Company Overview - XPLR Infrastructure, LP, formerly known as Nextera Energy Partners, LP, focuses on acquiring, owning, and managing contracted clean energy projects in the United States, including wind and solar power projects and a natural gas pipeline [2]. Allegations in the Class Action - The lawsuit claims that during the class period, the defendants made misleading statements about XPLR's operations as a yieldco, which is a business model focused on delivering cash distributions to investors [3]. - Specific allegations include: - XPLR was struggling to maintain its yieldco operations [3]. - Defendants entered financing arrangements to temporarily alleviate operational issues while downplaying associated risks [3]. - The company could not resolve these financings before maturity without risking significant unitholder dilution [3]. - Defendants planned to halt cash distributions to redirect funds to resolve financing issues [3]. - The yieldco business model and distribution growth rate were deemed unsustainable [3]. - Public statements made by the defendants were materially false and misleading [3]. Market Reaction - On January 28, 2025, XPLR announced it would suspend cash distributions to common unitholders and abandon its yieldco model, leading to a significant drop in the stock price from $15.80 to $10.49 per unit, a decline of nearly 35% [4].